Navigation Links
ViroPharma Incorporated Reports Third Quarter 2008 Financial Results
Date:10/29/2008

ital increased by $28 million to $672 million;

-- Cash, cash equivalents and short-term investments grew by $35 million

to $668 million; and

-- 15th consecutive quarter of positive cash flow and profitability

achieved.

Net sales of Vancocin were $65.9 million for the third quarter of 2008 and $182.3 million for the first nine months of 2008, as compared to $50.9 million and $156.1 million in the respective 2007 periods.

Operating income in the third quarter and nine-months ended September 30, 2008 was $32.8 million and $82.1 million, respectively, compared to $27.9 million and $96.7 million in the third quarter and nine months of 2007, respectively. Operating income increased in the third quarter primarily due to higher sales. Operating income for the nine months ended September 30, 2008 decreased primarily due to higher R&D and SG&A costs partially offset by higher net sales.

"Our execution and achievement continued throughout ViroPharma during the third quarter of 2008," commented Vincent Milano, ViroPharma's president and chief executive officer. "As demonstrated by the record net sales of Vancocin during the third quarter of the year, the need for this proven safe and effective treatment for Clostridium difficile disease remains at an all time high, and we believe that our initial sales effort may be influencing appropriate usage. The momentum in our maribavir program continued to build as well, as we made great progress in advancing the two largest CMV studies ever conducted in the transplant setting. We expect this momentum to continue toward our planned initial NDA, MAA, and NDS filings in the third quarter of 2009."

Continued Milano, "We are also pleased to have closed our acquisition of Lev since the end of the third quarter, and are rapidly moving towards the full commercial launch of Cinryze, an important drug to prevent attacks of hereditary angioedema in a population with few treatment options."
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
2. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
3. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
4. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
5. ViroPharma Provides Update on Vancocin(R)
6. ViroPharma Augments Senior Management
7. ViroPharma to Present at the 26th Annual JP Morgan Healthcare Conference
8. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
9. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results
10. ViroPharma to Present at the UBS Global Life Sciences Conference
11. ViroPharma to Present at the Maxim Group First Annual Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... India Network Foundation, a non-profit US based ... today a new version of “ EasySelect ”, a ... plan for their visiting parents. The technology tool is ... process when choosing an insurance plan by showing the ... few clicks. Many elderly Asian Indian parents often find ...
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is ... developing, producing and marketing of a series of induction ... their new series of induction brazing equipments . ... induction brazing refers to the joining of ... and heat. The manager says that there are fundamental ...
(Date:12/25/2014)... 2014 The microscopy market is ... to reach $5,756.0 million by 2019. Optical microscopy ... The electron microscopes product segment is expected to ... , Rising focus on nanotechnology, technological advancements, and ... microscopy market. , Get Full Copy of Report ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 ... BambooFlooringChina.com combines beauty, strength and durability. Today, the ... promotion, which is valid until Jan. 30, 2015. ... grain of traditional hardwood. BambooFlooringChina.com is a well-known ... help consumers worldwide to find a reliable bamboo ...
(Date:12/25/2014)... The report “TS-1 (Colorectal Cancer) – ... current treatment landscape, unmet needs, current pipeline and commercial ... anti-cancer drug which is typically used for treating colorectal ... for treating gastric cancer and pancreatic cancer. TS-1 is ... was first approved in 1999 in Japan for the ...
Breaking Medicine News(10 mins):Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... of over $50 to,Doctors, ALBANY, N.Y., May ... Committee reported key legislation (see vote count,below) to ... in New York,State. Governor Paterson,s bill, A.11187, sponsored ... gifts of over $50 to doctors and,requires doctors ...
... Corporation, the,leader in dry-state, room temperature biosample management ... part of GE Healthcare, will,become a non-exclusive distributor ... The GenSolve DNA recovery kit enables FTA(R)1 ... archived samples with a simple, user-friendly,and reliable procedure. ...
... 29 Three of the most terrifying words in,the English ... word,"prostate" and the fear factor rises even higher, since prostate ... but with early,detection is very curable., Give a gift ... a simple,blood test to screen for prostate cancer. If there ...
... sex, age and ethnicity has a significant impact on ... study led by researchers at the University of Southern ... , While age and ethnicity are well-established factors ... that gender also plays an important role in overall ...
... read and have good phonetic skills - the ability to ... poor spellers. In a paper published in the May 2008 ... School of Psychology of Leicester, UK, show that this subgroup ... other poor spellers. , The three-year study was carried out ...
... Calif., May 29 Alsius Corporation,(Nasdaq: ... temperature,management (IVTM(TM)) therapies for critically ill patients, ... Partners, L.P. to provide,intravascular temperature management products ... is the fifth contract we have been ...
Cached Medicine News:Health News:Assembly on the Move for Rx Reform 2Health News:Assembly on the Move for Rx Reform 3Health News:Whatman, Now Part of GE Healthcare, to Distribute GenVault DNA Recovery Kits in North America 2Health News:Whatman, Now Part of GE Healthcare, to Distribute GenVault DNA Recovery Kits in North America 3Health News:Give the Man in Your Life the Gift of Health 2Health News:USC study finds sex, age and ethnicity assciated with colorectal cancer survival 2Health News:Alsius Corporation Awarded Three-Year Agreement With Premier, Inc. 2Health News:Alsius Corporation Awarded Three-Year Agreement With Premier, Inc. 3
(Date:12/24/2014)... /CNW/ -   The ... Canada tests confirmed it contains two undeclared amphetamine-like drug ... The distributor, Empire Health Distribution of Terrebonne, ... stores across Canada .  Jetfuel Superburn ... loss and increased energy. What consumers ...
(Date:12/24/2014)... 24, 2014  Commonwealth Cornerstone Group (CCG) today announced the ... on Tuesday to help fund the expansion and consolidation of ... Sharon . PHN is the ... . It is the largest employer in ... people on staff. Currently, PHN Sharon offers scattered ...
(Date:12/24/2014)... , Dec. 24, 2014 Soligenix, ... late-stage biopharmaceutical company developing products that address unmet ... and biodefense, announced today that on December 24, ... offering. The Company raised approximately $2.3 ... intends to use the net proceeds from the ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
... DUSA Pharmaceuticals, Inc. ® (Nasdaq GM: DUSA), ... ® Photodynamic Therapy (PDT) and other products focused ... Doman, President and Chief Executive Officer, will present a ... Conference on Thursday, November 18, 2010 at 8:30 a.m. ...
... in Phase... -- ITTIGEN and BERN, Switzerland, November 11, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
Cached Medicine Technology:Pevion's Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study 2Pevion's Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study 3Pevion's Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study 4Pevion's Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study 5Pevion's Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study 6Pevion's Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study 7Pevion's Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study 8Pevion's Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study 9
SAS Strep A Test is a rapid visual test for the presumptive qualitative detection of Group A Streptococcal antigen from throat swab specimens. Group A streptococcus is the principal cause of respirat...
Poly stat Strep A is a lateral flow, one-step immunoassay for the rapid, qualitative detection of Group A Streptococcal antigen from throat swabs. The test is intended for use as an aid in the diagn...
HemataSTAT II has a manual reader. It uses both 0.5 and 1.1 ID capillary tubes., , Spins in just 60 seconds , Built-in reader with LCD display , Accuracy comparable to NCCLS reference method , Lid lo...
... offers unparalleld speed, providing accurate, reliable ... only 10 ul of blood. Fast ... comprehensive patient care by spending more ... S System is easy-to-use, accurate, convenient, ...
Medicine Products: